QAAHBX — T. Rowe Price Health Sciences Portfolio
Data updated: 2026-05-28
QAAHBX — T. Rowe Price Health Sciences Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $662.62M AUM · 1.10% expense ratio · 10.6% 1-yr return. From SEC regulatory filings.
QAAHBX Fund Overview
QAAHBX — T. Rowe Price Health Sciences Portfolio is a US mutual fund managed by T. Rowe Price Equity Series, Inc., categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: T. Rowe Price Equity Series, Inc.
- Category: United States Health Care Equity
- Assets under management: $662.62M
- 1-year return: 10.6%
- Ticker: QAAHBX
- SEC CIK: 0000918294
- SEC series ID: S000002083
- Share class ID: C000005449
QAAHBX Holdings
Top 10 holdings of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 10.21% |
| Thermo Fisher Scientific, Inc. | 4.08% |
| Intuitive Surgical, Inc. | 3.68% |
| Stryker Corp. | 3.49% |
| Merck & Co. Inc. | 3.46% |
| Astrazeneca PLC | 3.18% |
| Unitedhealth Group, Inc. | 3.10% |
| Argenx SE - ADR | 2.93% |
| Abbvie, Inc. | 2.88% |
| Regeneron Pharmaceuticals | 2.68% |
QAAHBX Portfolio Allocation
Asset-class allocation of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 0.4% |
| Fixed Income | 0.1% |
QAAHBX Performance
Total returns for QAAHBX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -6.3% |
| 1 year | 10.6% |
| 3 years (annualised) | 5.6% |
| 5 years (annualised) | 2.6% |
QAAHBX Risk Information
Risk metrics for QAAHBX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.7%
QAAHBX Costs and Fees
QAAHBX costs about $110 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.10%
- Gross expense ratio: 1.10%
- Portfolio turnover: 65%
- Brokerage commissions: 2.93 bps of average net assets (SEC N-CEN)
QAAHBX Cashflows
Over the 12 months to 2026-03, T. Rowe Price Health Sciences Portfolio had net outflows of $39.18M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$5.61M |
| 2026-02 | −$3.45M |
| 2026-01 | −$13.18M |
| 2025-12 | $19.61M |
| 2025-11 | −$2.32M |
| 2025-10 | −$5.41M |
QAAHBX Debt Constituents
Largest debt holdings of T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Immunocore Holdings Cb 2.50% 2/30 | 0.10% |
| Delfi Diagnostics CVT Prom Note PP | 0.01% |
| Kartos Therapeutics CVT Prom Note PP | 0.01% |
| Reflexion Med CVT Note issued 081325 PP | 0.01% |
| Reflexion Med CVT Note issued 072525 PP | 0.01% |
| Reflexion Med CVT Note issued 082725 PP | 0.00% |
QAAHBX Prospectus and SEC Filings
Official T. Rowe Price Health Sciences Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.